Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Theoretical Michaelis-Menten elimination model for propranolol.

J McAinsh, M A Gay

    European Journal of Drug Metabolism and Pharmacokinetics
    |July 1, 1985
    PubMed
    Summary

    A new pharmacokinetic model explains drug behavior, particularly propranolol (Inderal). Bioavailability, measured by area under the curve, depends heavily on absorption half-life, matching experimental data.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Oral transmucosal etomidate in volunteers.

    Anesthesiology·1998
    Same author

    Beta blockers and quality of life.

    The British journal of clinical practice·1992
    Same author

    Atenolol and ischaemic heart disease: an overview.

    Current medical research and opinion·1991
    Same author

    A study of the pharmacokinetics and pharmacodynamics of nifedipine in combination with atenolol.

    Biopharmaceutics & drug disposition·1991
    Same author

    Pharmacokinetic and pharmacodynamic studies in man with an antianginal agent 'Visacor'.

    Biopharmaceutics & drug disposition·1990
    Same author

    Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses.

    Cephalalgia : an international journal of headache·1990

    Area of Science:

    • Pharmacokinetics
    • Drug Metabolism
    • Pharmacology

    Background:

    • Michaelis-Menten kinetics are crucial for understanding drug elimination.
    • Propranolol (Inderal) pharmacokinetics, especially sustained-release formulations (Inderal LA), require detailed modeling.
    • Plasma drug concentration-time profiles are key to assessing bioavailability.

    Purpose of the Study:

    • To develop a pharmacokinetic model incorporating Michaelis-Menten elimination for drugs, specifically propranolol.
    • To elucidate the relationship between the area under the plasma concentration-time curve and the absorption rate constant.
    • To explain observed pharmacokinetic behaviors of Inderal and Inderal LA using the developed model.

    Main Methods:

    • Development of a theoretical pharmacokinetic model.
    • Application of Michaelis-Menten kinetics for drug elimination.
    • Analysis of the relationship between area under the curve and absorption rate constant.

    Main Results:

    • The model successfully explains various pharmacokinetic aspects of propranolol and Inderal LA.
    • A strong dependence of bioavailability (area under the curve) on absorption half-life was identified.
    • Model predictions align with experimentally observed pharmacokinetic data.

    Conclusions:

    • The developed pharmacokinetic model provides a robust framework for understanding propranolol behavior.
    • Absorption half-life is a critical determinant of propranolol bioavailability.
    • The model offers valuable insights into the performance of sustained-release drug formulations.

    Related Experiment Videos